GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aptabio Therapeutics Inc (XKRX:293780) » Definitions » Total Assets

Aptabio Therapeutics (XKRX:293780) Total Assets : ₩83,322 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aptabio Therapeutics Total Assets?

Aptabio Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was ₩83,322 Mil.

During the past 12 months, Aptabio Therapeutics's average Total Assets Growth Rate was 31.50% per year. During the past 3 years, the average Total Assets Growth Rate was 6.70% per year. During the past 5 years, the average Total Assets Growth Rate was 85.40% per year.

During the past 7 years, Aptabio Therapeutics's highest 3-Year average Total Assets Growth Rate was 323.00%. The lowest was 6.70%. And the median was 156.00%.

Total Assets is connected with ROA %. Aptabio Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 was -37.32%. Total Assets is also linked to Revenue through Asset Turnover. Aptabio Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 was 0.01.


Aptabio Therapeutics Total Assets Historical Data

The historical data trend for Aptabio Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptabio Therapeutics Total Assets Chart

Aptabio Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial 77,404.26 75,443.71 64,910.60 56,113.73 92,519.12

Aptabio Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100,944.95 92,519.12 89,883.37 88,756.52 83,322.30

Aptabio Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aptabio Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=61363.391+31155.725
=92,519

Aptabio Therapeutics's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=48966.642+34355.66
=83,322

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptabio Therapeutics  (XKRX:293780) Total Assets Explanation

Total Assets is connected with ROA %.

Aptabio Therapeutics's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=-32105.972/( (88756.518+83322.302)/ 2 )
=-32105.972/86039.41
=-37.32 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aptabio Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=859.408/( (88756.518+83322.302)/ 2 )
=859.408/86039.41
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aptabio Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Aptabio Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptabio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
13, Heungdeok 1-ro, Giheung-gu, Tower 504, Gyeonggi-do, Yongin-Si, KOR, 16954
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.

Aptabio Therapeutics Headlines

No Headlines